ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Acumen Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Jul 13, 2021 5:30pm

127 Views

Post# 33537392

RE:Acumen Pharmaceuticals Inc

Does sounds very familiar! "Highly selective for oligomers, the toxic AO species, relative to other anti-amyloid mAbs that are less selective and/or target different amyloid species, such as monomers or plaques." Acumen Pharmaceutical Inc. PPS $18+. PMN $0.18+ Nasdaq is where we need to be. G1945V

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market